The European and American guidelines on dyslipidemia management overlap but also diverge in critical ways. A Johns Hopkins cardiologist highlights similarities and differences.
COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types
Prior SARS-CoV-2 infection was associated with a 2-fold increased risk for MACE for up to 3 years, even among people with no history of CVD, in a new analysis of UK Biobank data.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Strong Link Between Increasing Lp(a) Level and Recurrent ASCVD Events Makes Screening Essential, Investigator Warns
A continuous increase in ASCVD risk was seen with higher levels of lipoprotein(a) in the largest study to date of the relationship.
Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?
Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.
Statin Plus Ezetimibe Outperforms High-Dose Statins in LDL-C Reduction: Daily Dose
Your daily dose of the clinical news you may have missed.
Finerenone Improves Outcomes in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction
ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.